Browsing Tag
ALX Oncology
4 posts
ALX Oncology turns to biomarker-led development after evorpacept gastric cancer results
ALX Oncology’s evorpacept shows stronger activity in CD47-high HER2 tumors as the company seeks partners and prioritizes breast cancer.
ALX Oncology gets EC’s orphan drug status for evorpacept in gastric cancer
ALX Oncology Holdings, an Australian immuno-oncology company focusing on CD47 checkpoint pathway blocking therapies, declared a significant milestone…
ALX Oncology’s evorpacept gets FDA ODD for gastric cancer and gastroesophageal junction cancer
ALX Oncology said that its CD47 blocker evorpacept has secured orphan drug designation (ODD) from the US Food…
ALX Oncology raises $105m to advance clinical development of ALX148
ALX Oncology, a clinical-stage immuno-oncology company based in California, has raised $105 million in a Series C equity…